Absco Therapeutics, Inc. D/b/a Abscotx

Absco Therapeutics is a biopharmaceutical company developing drug delivery technologies using thermogelling polymers that transform from liquid to solid at body temperature to create controlled-release depots for immune-modulating therapies. The company's lead program, ABS005, is a non-surgical treatment candidate for cervical intraepithelial neoplasia (CIN2/3) that combines a clinically validated drug with the company's polymer system for sustained intralesional delivery.